lithium carbonate ER / Generic mfg. - LARVOL DELTA

Mitochondrial Insights into Lithium Response in Bipolar Disorder: A State-of-the-Art Review. (PubMed, Neuropsychobiology) - "We highlight the need for unified protocols, integration of omics technologies, extracellular vesicle-based sampling strategies, and improved in vitro and in vivo models. A better understanding of mitochondrial signatures related to lithium may enable biomarker discovery and advance personalized treatment in BD."

Journal • Review • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • MFN2

Unstable Lithium Levels in a Bodybuilder With Bipolar Disorder: The Impact of Sodium Intake and Anabolic Steroid Use. (PubMed, Prim Care Companion CNS Disord) - No abstract available

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Challenges of Treatment-Resistant Bipolar Depression in the Elderly: A Case Study of Successful Modafinil Augmentation. (PubMed, Cureus) - "Modafinil may be a safe and effective adjunct in treatment-resistant bipolar depression, especially when conventional therapies are contraindicated. Its use may extend beyond elderly populations to adults with similar clinical challenges."

Journal • Ataxia • Bipolar Disorder • Chronic Kidney Disease • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Nephrology • Psychiatry • Renal Disease

Lithium and valproic acid in bipolar disorder: Beyond mood stabilization, the overlooked role of sleep. (PubMed, World J Psychiatry) - "Polysomnography, although the gold standard, is not always practical; therefore, actigraphy and wearable technologies represent feasible alternatives to capture objective sleep patterns. This letter emphasizes the importance of integrating objective, scalable technologies and pharmacological monitoring into longitudinal designs to clarify whether improvements in sleep translate into better clinical outcomes and reduced relapse risk in bipolar disorder."

Journal • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry

Genistein Exerts Neuroprotective Effects in an Ouabain-Induced Model of Bipolar Disorder: Behavioral and Molecular Insights. (PubMed, Neurochem Res) - "Furthermore, genistein restored the normal architecture in both hippocampal and cortical H&E-stained sections. Taken together, genistein was able to activate the Na⁺/K⁺-ATPase signalosome via a multifaceted mode of action, exerting a neuroprotective effect in an animal model of BD, promoting genistein as a therapeutic candidate for BD."

IO biomarker • Journal • B Cell Lymphoma • Bipolar Disorder • CNS Disorders • Depression • Hematological Malignancies • Leukemia • Lymphoma • Mental Retardation • Mood Disorders • Non-Hodgkin’s Lymphoma • Oncology • Psychiatry • BAX • EGFR

How Well Do We Know VPDB-Part 2: Interlaboratory Assessment of Existing δ13CVPDB Reference Materials. (PubMed, Rapid Commun Mass Spectrom) - "In January 2024, the IAEA experts meeting endorsed both δ13C scales that are currently used within the scientific community: the Vienna Peedee belemnite (VPDB) δ13C scale defined by NBS 19 with a value of +1.95‰ exactly, and the VPDB-LSVEC scale defined by NBS 19 and the lithium carbonate LSVEC with a value of -46.60‰ exactly...Within their measurement uncertainty they are identical to previously published values. Finally, we provide values on the δ13CVPDB and δ13CVPDB-LSVEC scales for some RMs that are routinely used in elemental analysis-isotope ratio mass spectrometry."

Journal

Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder. (PubMed, J Affect Disord) - "Baseline TSH levels were associated with ketamine's antidepressant and anti-anhedonic effects in BD but not MDD. These findings suggest that TSH may serve as a predictive biomarker of response and highlight a potential thyroid-glutamate influence in ketamine's mechanism of action."

Journal • Bipolar Disorder • CNS Disorders • Depression • Endocrine Disorders • Major Depressive Disorder • Mood Disorders • Psychiatry • Suicidal Ideation

Overlap and Divergence in Ketamine and Lithium Response in Bipolar Disorder: A Scoping Review. (PubMed, Pharmaceuticals (Basel)) - " Overall, existing data support mechanistic overlap but clinical divergence between ketamine and lithium responders, though this is confounded by sampling bias. We must therefore undertake longitudinal studies of prophylactic lithium therapy among patients with BD who received ketamine for acute antidepressant treatment in order to investigate if responsiveness to ketamine predicts response to lithium, and establish control over BD earlier in the course of illness."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Lithium Therapy-Associated Thyroid Alterations Mimicking Thyroid Malignancy: A Diagnostic Pitfall. (PubMed, Int J Surg Pathol) - "The patient's long history of lithium therapy was instrumental in recognizing the functional origin of the thyroid changes, which, if identified earlier, could have prevented unnecessary completion surgery. This report highlights the evolving diagnostic criteria for thyroid tumors, illustrating how lithium-associated thyroiditis can mimic malignancy and lead to overtreatment if historical context is not considered."

Journal • Bipolar Disorder • CNS Disorders • Endocrine Disorders • Fibrosis • Immunology • Oncology • Psychiatry • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma

Medium cut-off membrane expanded hemodialysis for Lithium removal: a case report. (PubMed, Front Toxicol) - "This case described the potential utility of HDx with the MCO membrane (Theranova® 400) in managing severe lithium poisoning, achieving effective and sustained drug clearance. While HDx-MCO may offer a viable alternative to conventional HD, especially in settings where enhanced solute removal is desirable, further studies are needed to determine its efficacy and clinical role in lithium toxicity management."

Journal • Bipolar Disorder • CNS Disorders • Endocrine Cancer • Mood Disorders • Psychiatry

Lithium Point-of-Care Testing to Improve Adherence to Monitoring Guidelines and Quality of Maintenance Therapy: Protocol for a Randomised Feasibility Trial. (PubMed, Pharmaceuticals (Basel)) - "The proportion of patients meeting guidelines for lithium monitoring will be examined, alongside measures of acceptability, wellbeing, and health economic data. POC testing has the potential to significantly improve patient safety and satisfaction with lithium treatment."

Journal • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Lithium-Induced Modulation of Proliferation and Apoptosis in an In Vitro Model of Colorectal Cancer. (PubMed, Int J Mol Sci) - "We assessed the cytotoxic and molecular effects of lithium carbonate (Li2CO3) and lithium chloride (LiCl) in two CRC cell lines (HCT-116 and SW-620) and a non-tumorigenic line (CRL-1790)...Overall, these findings indicate that lithium salts selectively reduce CRC cell viability, impair stem-like characteristics, and induced caspase-independent apoptosis. Therefore, we expand the proof of concept of the potential of lithium-based compounds as low-toxicity adjuvant agents in colorectal cancer therapy."

Journal • Preclinical • Colorectal Cancer • Oncology • Solid Tumor • ANXA5 • CASP3 • MYC

Evaluation of Pharmacological Treatments for Infantile Spasms: A Review of ClinicalTrials.gov (AES 2025) - "Key elements extracted included therapeutic agents, study design, primary endpoints, and reported efficacy and safety outcomes. The included trials assessed a range of pharmacologic agents, spanning both established therapies (ACTH, vigabatrin, prednisolone) and investigational compounds (cannabidiol, ganaxolone, TAK-935, tricaprilin, pyridoxine, lithium carbonate). This review highlights the diversity of pharmacologic interventions under investigation for IS and reinforces the role of both established and emerging therapies. While completed trials provide valuable insight into evolving treatment strategies, important gaps remain—particularly the lack of patient-level outcomes and long-term neurodevelopmental data. Future research should focus on stratified study designs, biomarker-informed approaches, and extended follow-up to optimize treatment selection and improve clinical outcomes in this high-risk pediatric population."

Clinical • Review • CNS Disorders • Epilepsy • Gastrointestinal Disorder

Association of lithium treatment with cardiac structure and circulating leukocyte distribution in patients with bipolar disorder. (PubMed, J Affect Disord) - "Lithium may mitigate the risk of heart failure, as indicated by the reduced LV concentricity and LV RWT, in patients with BD through the regulation of leukocytes. Future research should strengthen these findings by incorporating markers that reflect leukocyte dynamics in the myocardium."

Journal • Bipolar Disorder • Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Inflammation • Mood Disorders • Psychiatry

Sleep quality in bipolar disorder: A comparative study of treatment with lithium and valproic acid. (PubMed, World J Psychiatry) - "Patients in the lithium group showed significantly better habitual sleep efficiency and fewer sleep disturbances compared to those receiving valproic acid, although other sleep parameters did not differ. These findings suggest a potential advantage of lithium in certain aspects of sleep quality in BD patients under remission. Future studies using objective sleep measures and longitudinal designs are warranted to confirm these findings."

Journal • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry • Sleep Disorder

Prevalence of dermatologic side effects of mood stabilizers in bipolar disorder: A systematic review and meta-analysis. (PubMed, J Psychiatr Res) - "Mood stabilizers showed varying levels of dermatologic AEs, but severe reactions were rare. Future studies should explore factors influencing these outcomes, their impact on quality of life and treatment participation, and potential management strategies."

Adverse events • Journal • Retrospective data • Review • Alopecia • Bipolar Disorder • CNS Disorders • Dermatology • Mood Disorders • Psychiatry • Steven-Johnson Syndrome

Lithium Carbonate Conversion to Lithium Hydroxide Using Calcium Hydroxide: Equilibrium is Governed by Vaterite Formation. (PubMed, Inorg Chem) - "Notably, the presence of vaterite alongside calcite significantly affects the equilibrium concentration of LiOH, underscoring the role of solid-phase composition in governing reaction thermodynamics. These findings provide a deeper understanding of the causticization mechanism and offer actionable insights for optimizing LiOH production in industrial settings."

Journal

Unveiling the Mechanisms of Improved Stability and Performance via Tetraalkyl-Type Ionic Liquids: Suppression of Organic Solid Electrolyte Interface Formation in Lithium-Mediated Nitrogen Reduction. (PubMed, ACS Appl Mater Interfaces) - "Distinct differences in SEI composition and morphology were observed, with EtOH promoting rapid and extensive formation of irregular organic SEI layers, predominantly lithium ethoxide (LiOEt) and lithium carbonate (Li2CO3). Conversely, TBACl conditions suppressed organic SEI growth through stable electric double layer formation by TBA+ ions, significantly limiting free THF molecules near the electrode surface and, thus, reducing unwanted organic SEI components. Our results highlight the critical role of proton carrier selection in controlling SEI formation, emphasizing TBACl's advantages for enhancing Li-NRR stability and efficiency."

Journal

The effects of Lithium on Beta-amyloid deposition and tau phosphorylation: A systematic review. (PubMed, J Affect Disord) - "Lithium potentially reduces intracerebral amyloid deposition and tau phosphorylation in AD animal models and may reverse associated cognitive deficits. Further research should seek to replicate similar findings in larger samples and explore lithium's optimal dosage range in promoting intracerebral amyloid clearance."

Journal • Review • Alzheimer's Disease • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Dementia • Developmental Disorders • Mood Disorders • Psychiatry • Targeted Protein Degradation

Real-world analysis of pharmacological treatments to prevent relapse after electroconvulsive therapy for major depressive disorder: A nationwide cohort study. (PubMed, Transl Psychiatry) - "The most common psychiatric drugs dispensed after ECT were antipsychotics (39.7%), mirtazapine (38.0%), and selective serotonin reuptake inhibitors (SSRI) (35.9%)...Antipsychotics were associated with a greater risk of relapse (aHR 1.17, 95% CI 1.05-1.31, p = 0.006). For other pharmacological treatments there were no associations with risk of relapse."

Journal • Real-world evidence • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Analytical imprecision and therapeutic intervals for lithium - Are there Implications for old age patients with bipolar disorder? (PubMed, Clin Biochem) - "Routine colorimetric methods used for lithium measurements have adequate precision and detection capabilities in the therapeutic windows proposed by the ISBD task force. In addition, the proposed therapeutic intervals are verifiable by real-world patient data."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

A Population-Based Cohort Study of Early Infant Feeding Initiation in Maternal Bipolar Disorder. (PubMed, Bipolar Disord) - "These data support the case for additional supports and services to support mothers with bipolar disorder in early infant feeding initiation, and for research into how to best utilize medications in lactation."

Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Bipolar disorder and inflammation: a clinical study of NLR and dNLR across mood states and subtypes. (PubMed, World J Biol Psychiatry) - "NLR and dNLR appear to act as state-dependent peripheral markers in BD, reflecting acute psychotic mania and lithium modulation rather than trait inflammation. These preliminary findings warrant confirmation in larger, longitudinal cohorts."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

The history of lithium therapy in bipolar disorder (Neuroscience 2025) - "In the 1960s, lithium grew popular again due to an increasing number of clinical trials by several researchers such as Ronald Fieve, which provided the evidence for FDA approval in 1970. Since the 1990s, lithium use has declined, and it is currently underutilized-likely due to the availability of mood stabilizing antipsychotics and antiseizure medications."

Bipolar Disorder • CNS Disorders • Depression • Epilepsy • Mood Disorders • Psychiatry

The potential of GSK3 inhibitors as a therapeutic approach for bipolar disorder (Neuroscience 2025) - "BRD7355 and the reference dual inhibitor PF-04802367 (PF-367) were efficacious in hyperdopaminergic models, including amphetamine-induced hyperlocomotion (AIH) and the open field test in Grin2a KO mice—a genetic schizophrenia risk model...Ongoing studies are evaluating BRD8412 (GSK3⍺-selective) in parallel assays. Additional work aims to assess the efficacy of these inhibitors across other genetically driven models to further define the therapeutic landscape of isoform-specific GSK3 inhibition."

Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia • GRIN2A